Centre steps up oversight on GLP-1 drugs amid concerns over 'improper' practices

India's drug regulator is increasing oversight of GLP-1 weight loss drugs. Inspections across 49 entities revealed violations like unauthorized sales and improper prescriptions. Strict actions, including license cancellation, will be taken against non-compliant firms. An advisory also prohibits misleading advertisements. These medications should only be used under qualified medical guidance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YFaK8JV
via IFTTT